Journal article icon

Journal article

A single dose of anti-miR-122, RG-101, in CHC patients results in NK cell normalization with no effect on HCV-specific CD8+ T cell function

Abstract:

MicroRNA-122 (miR-122) is an important host factor for the hepatitis C virus. Treatment with RG-101, a GalNAc conjugated anti-miR-122 oligonucleotide, resulted in a significant viral load reduction in patients with chronic hepatitis C (CHC) infection. Here, we analyzed the effects of RG-101 therapy on antiviral immunity. 32 CHC patients HCV genotype 1, 3 and 4 received a single subcutaneous administration with RG-101 at 2 mg/kg (n=14), 4 mg/kg (n=14) or placebo (n=2 per dosing group). Plasma ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/hep.29148

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
Expand authors...
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
Expand funders...
Publisher:
Wiley Publisher's website
Journal:
Hepatology Journal website
Volume:
66
Issue:
1
Pages:
57–68
Publication date:
2017-03-01
Acceptance date:
2017-02-14
DOI:
EISSN:
1527-3350
ISSN:
0270-9139
Source identifiers:
680422
Keywords:
Pubs id:
pubs:680422
UUID:
uuid:04bf4fe8-6846-43b1-859a-3c83422a947d
Local pid:
pubs:680422
Deposit date:
2017-02-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP